Abstract
Continuous grinding kinetics of Ethenzamide powder, as a model active pharmaceutical ingredient (API) was investigated by fluidized-bed jet-milling. Because the oversize fractions after the classification were well fitted by a modified Rosin-Rammler distribution function, an equation of grade efficiency curve was obtained, which was also characteristic of API. A continuous grinding model was developed on the basis of a batch model by using 1st Kapur function relating grinding rate, the grade efficiency curve, and the overall process flow model consisting of grinding, classification, and mixing zones. The residual ratio obtained was well fitted to the experimental results except for the particle size range smaller than 4 μm and larger than 100 μm. Furthermore, because the volume of the active grinding zone adopted as the fitting parameter was found to be 5 cm3 in all experiments and the value was considered to be appropriate dimensionally, this result supports the reliability of the model.
| Original language | English |
|---|---|
| Pages (from-to) | 347-355 |
| Number of pages | 9 |
| Journal | Drug Development and Industrial Pharmacy |
| Volume | 32 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2006 |
| Externally published | Yes |
Fingerprint
Keywords
- Continuous grinding
- Ethenzamide
- Fluidized-bed jet-mill
- Kinetics
- Mathematical model
ASJC Scopus subject areas
- Molecular Medicine
- Organic Chemistry
- Drug Discovery
- Pharmacology
Cite this
Continuous grinding kinetics of ethenzamide particles by fluidized-bed jet-milling. / Fukunaka, T.; Golman, B.; Shinohara, K.
In: Drug Development and Industrial Pharmacy, Vol. 32, No. 3, 2006, p. 347-355.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Continuous grinding kinetics of ethenzamide particles by fluidized-bed jet-milling
AU - Fukunaka, T.
AU - Golman, B.
AU - Shinohara, K.
PY - 2006
Y1 - 2006
N2 - Continuous grinding kinetics of Ethenzamide powder, as a model active pharmaceutical ingredient (API) was investigated by fluidized-bed jet-milling. Because the oversize fractions after the classification were well fitted by a modified Rosin-Rammler distribution function, an equation of grade efficiency curve was obtained, which was also characteristic of API. A continuous grinding model was developed on the basis of a batch model by using 1st Kapur function relating grinding rate, the grade efficiency curve, and the overall process flow model consisting of grinding, classification, and mixing zones. The residual ratio obtained was well fitted to the experimental results except for the particle size range smaller than 4 μm and larger than 100 μm. Furthermore, because the volume of the active grinding zone adopted as the fitting parameter was found to be 5 cm3 in all experiments and the value was considered to be appropriate dimensionally, this result supports the reliability of the model.
AB - Continuous grinding kinetics of Ethenzamide powder, as a model active pharmaceutical ingredient (API) was investigated by fluidized-bed jet-milling. Because the oversize fractions after the classification were well fitted by a modified Rosin-Rammler distribution function, an equation of grade efficiency curve was obtained, which was also characteristic of API. A continuous grinding model was developed on the basis of a batch model by using 1st Kapur function relating grinding rate, the grade efficiency curve, and the overall process flow model consisting of grinding, classification, and mixing zones. The residual ratio obtained was well fitted to the experimental results except for the particle size range smaller than 4 μm and larger than 100 μm. Furthermore, because the volume of the active grinding zone adopted as the fitting parameter was found to be 5 cm3 in all experiments and the value was considered to be appropriate dimensionally, this result supports the reliability of the model.
KW - Continuous grinding
KW - Ethenzamide
KW - Fluidized-bed jet-mill
KW - Kinetics
KW - Mathematical model
UR - http://www.scopus.com/inward/record.url?scp=33645308519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645308519&partnerID=8YFLogxK
U2 - 10.1080/03639040500519136
DO - 10.1080/03639040500519136
M3 - Article
C2 - 16556539
AN - SCOPUS:33645308519
VL - 32
SP - 347
EP - 355
JO - Drug Development and Industrial Pharmacy
JF - Drug Development and Industrial Pharmacy
SN - 0363-9045
IS - 3
ER -